Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

计划入组 217 人 · 首次发布于 2020 年 10 月 8 日

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

计划入组 95 人 · 首次发布于 2023 年 5 月 8 日

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

计划入组 108 人 · 首次发布于 2023 年 12 月 29 日

Her2-DIDT

Her2-IACS8803

HER2.taNK

Zymeworks

Canada

Nuvalent

United States

TYRA BIOSCIENCES, INC.

United States

Expert Emphasizes Critical Need for Comprehensive NGS Testing to Detect HER2 Alterations in NSCLC

Bayer's BAY 2927088 Advances to Phase 3 Trial for HER2-Mutated NSCLC

Distinct Mechanisms of HER2-Targeting Agents in NSCLC: Understanding TKIs vs ADCs